Dr. Sanjay Mukhopadhyay Cleveland ClinicUSA

Dr. Sanjay Mukhopadhyay
Dr. Mukhopadhyay is Director of Pulmonary Pathology at the Cleveland Clinic, Associate Editor (Pulmonary) for the American Journal of Clinical Pathology and Associate Editor (Social Media) for Modern Pathology. He attended medical school in India and completed pathology residency training at the All India Institute of Medical Sciences followed by a second pathology residency at SUNY Upstate Medical University (Syracuse, NY). After a pulmonary pathology fellowship at the Mayo Clinic (Rochester, MN), he was recruited back to Syracuse and stayed on as faculty for next 6 years, rising to the rank of tenured Associate Professor in 2011. In 2013, he joined the department of pathology at the Cleveland Clinic. His interests include granulomatous lung diseases (including infections), interstitial lung disease, smoking-related lung disease, and lung cancer. The pulmonary pathology service at Cleveland Clinic signs out 5000 cases a year and supports a large group of ILD pulmonologists and several thoracic surgeons. The lung transplant service is one of the busiest in the world. Dr. Mukhopadhyay has authored more than 120 publications in indexed, peer-reviewed journals, including 47 first-authored papers. He is the author of a textbook on non-neoplastic lung pathology published by Cambridge University Press in 2016 and a textbook of thoracic pathology to be published by Innovative Science Press in 2022. His studies have been published in the American Journal of Surgical Pathology, American Journal of Clinical Pathology, Modern Pathology, Human Pathology, Archives of Pathology and Laboratory Medicine and Chest. In 2011, he was invited to join the faculty of the prestigious USCAP Long Course in Pulmonary Pathology. He has received several teaching awards, served on the abstract review committees of the USCAP and CAP for several years, moderated platform sessions at USCAP, and taught two USCAP Short Courses. Since 2016, he has pioneered the use of online platforms for teaching lung pathology globally, for which The Pathologist magazine named him to its “Power List” for 4 years in a row (2018-2021). In 2018, Dr. Mukhopadhyay first-authored a landmark study that led to FDA approval for whole slide imaging for primary diagnosis in surgical pathology in the United States. This was followed by two highly cited studies of the effects of vaping on the lung and autopsy findings in COVID-19 that generated intense interest in the national news media and online. In 2020, Dr. Mukhopadhyay was featured in a New York Times video on COVID-19 and ARDS that has been viewed more than 2 million times.

23 June 2022

Time Session